Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income (Unaudited) (USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended		6 Months Ended
	Jan. 31, 2015	Jan. 31, 2014	Jan. 31, 2015	Jan. 31, 2014
Condensed Consolidated Statements of Income and Comprehensive Income (Unaudited) [Abstract]
Net sales	$ 18,189	$ 15,096	$ 34,836	$ 30,626
Cost of sales	8,605	6,698	15,982	13,304
Gross profit	9,584	8,398	18,854	17,322
Operating expenses
Research and development	1,028	1,513	2,227	2,710
Sales and marketing	3,643	3,630	7,339	7,205
Medical device excise tax	116	115	244	240
Exit costs	657	514	719	514
General and administrative	2,942	3,003	5,970	5,638
Total operating expenses	8,386	8,775	16,499	16,307
Operating income (loss)	1,198	(377)	2,355	1,015
Other income (expense)
Investment income	1	3	2	6
Interest expense	(14)	0	(14)	0
Total other income (expenses)	(13)	3	(12)	6
Income (loss) from operations before provision (benefit) for income taxes	1,185	(374)	2,343	1,021
Provision (benefit) for income taxes	233	(149)	623	312
Net income (loss)	952	(225)	1,720	709
Earnings (loss) per share:
Basic earnings (loss) per share (in dollars per share)	$ 0.04	$ (0.01)	$ 0.07	$ 0.03
Diluted earnings (loss) per share (in dollars per share)	$ 0.04	$ (0.01)	$ 0.07	$ 0.03
Basic weighted average common shares outstanding (in shares)	25,364,574	25,309,641	25,352,279	25,301,830
Diluted weighted average common shares outstanding (in shares)	25,424,835	25,309,641	25,407,508	25,386,679
Net income (loss)	952	(225)	1,720	709
Foreign currency translation adjustment	(1,311)	(35)	(1,816)	140
Comprehensive (loss) income	$ (359)	$ (260)	$ (96)	$ 849